GlassScriptPhysician profile
Elvio E Ardilles
NPI 1518905322
$2,303.61
in general payments reported to CMS, 2019-2025
25 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $107 · 2022: $153 · 2023: $666 · 2024: $749 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.02 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $448.83 | 2020-2025 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $316.65 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.70 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $177.05 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Inari Medical, INC. | $173.34 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Coaptech, INC. | $147.64 | 2023 | Puma System |
| Abiomed | $129.31 | 2024 | Impella |
| Glaxosmithkline, LLC. | $121.83 | 2019-2023 | Trelegy Ellipta |
| Mylan Specialty L.P. | $74.55 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $69.76 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.22 | 2023 | Glassia, Hyqvia |
| Janssen Pharmaceuticals, INC | $49.75 | 2019-2022 | |
| Verona Pharma, INC. | $33.34 | 2025 | Ohtuvayre |
| Baxter Healthcare | $31.42 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $28.13 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $24.23 | 2023 | Airduo Digihaler |
| Mallinckrodt Hospital Products INC. | $23.56 | 2024 | Terlivaz |
| Novartis Pharmaceuticals Corporation | $22.78 | 2023 | |
| Paratek Pharmaceuticals, INC. | $21.57 | 2020 | |
| Viatris Specialty LLC | $20.93 | 2025 | Yupelri |
| Gilead Sciences, INC. | $20.62 | 2019 | |
| Circassia INC. | $19.05 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.01 | 2023 | Eliquis |
| Lilly USA, LLC | $16.78 | 2025 | Mounjaro, Zepbound |
| Electromed, INC. | $15.56 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elvio Ardilles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.